

SEMINARS IN THROMBOSIS AND HEMOSTASIS

Volume 23, Number 6

1997

Hypercoagulability and Antithrombotics

John W. Fenton, II, Ph.D.

Guest Editor

- 491 Preface**
John W. Fenton II, Ph.D.
- 493 Enzyme-Controlling Medicines: Introduction**
*Shosuke Okamoto, M.D., Akiko Hijikata-Okunomiya, Ph.D.,
Keiko Wanaka, Ph.D., Yoshio Okada, Ph.D., and Utako Okamoto, M.D.*
- 503 Novastan® (Brand of Argatroban): A Small-Molecule, Direct
Thrombin Inhibitor**
*Marcie J. Hursting, Ph.D., Kenneth L. Alford, Jean-Claude P. Becker, M.D.,
R. Lynn Brooks, James L. Joffrion, Gary D. Knappenberger,
Patricia W. Kogan, Ph.D., Timothy P. Kogan, Ph.D., Anthony A. McKinney,
and Richard P. Schwarz, Jr., Ph.D.*
- 517 Development of Argatroban, a Direct Thrombin Inhibitor, and
Its Clinical Application**
Takefumi Matsuo, M.D., Masanobu Koide, M.D., and Kazuomi Kario, M.D.
- 523 Effect of Argatroban, a Selective Thrombin Inhibitor, on Animal Models
of Cerebral Thrombosis**
Yoshikuni Tamao, Ph.D., and Ryoji Kikumoto, Ph.D.
- 531 Effect of the Thrombin Inhibitor Argatroban in Acute
Cerebral Thrombosis**
Shotai Kobayashi, M.D., and Yoshiaki Tazaki, M.D.

Continued



Thieme
New York • Stuttgart

- 535 Alterations of Platelet, Coagulation, and Fibrinolysis Markers in Patients with Acute Ischemic Stroke**
Shinichiro Uchiyama, M.D., Masako Yamazaki, M.D., Yukiko Hara, M.D., and Makoto Iwata, M.D.
- 543 Hypercoagulability in Heart Failure**
Syed M. Jafri, M.D.
- 547 The INR: A Perspective**
Roy E. Smith, M.D.
- 551 Is Low AT III a Significant Risk Factor for Coronary Artery Disease? Anecdotal Observations**
Malcolm J. Dickerson, M.D., F.A.A.F.P.
- 557 Regulation of Thrombosis and Hemostasis by Antithrombin**
Nobuo Sakuragawa, M.D., Ph.D.
- 563 Monitoring and Management of Anticoagulation in Children Requiring Extracorporeal Circulation**
Shobha Malviya, M.D.
- 569 Recognition and Management of Heparin-Induced Thrombocytopenia (HIT) and Thrombosis**
Barbara M. Alving, M.D., and Chitra Krishnamurti, Ph.D.
- 575 Clinical Trial Results with Hirudin and Bivalirudin for Acute Coronary Artery Syndromes**
Eric R. Bates, M.D.
- 583 Antithrombin III (AT III) Prevents LPS-Induced Pulmonary Vascular Injury: Novel Biological Activity of AT III**
Mitsuhiro Uchiba, M.D., and Kenji Okajima, M.D.
- 591 Antithrombin III in Hematopoietic Stem Cell Transplantation**
William D. Haire, Ph.D.
- 603 Abstracts of Current Literature**
Ernst Wenzel, M.D., Editor